Biotronik announced the first U.S. implant of their Pulsar-18 self expanding stent in the BIOFLEX-I IDE clinical trial. Carlos Mena of Yale University Medical Center performed the procedure.

Covidien announced the completion of enrollment in its DEFINITIVE AR (anti-restenosis) study. As the third study in the DEFINITIVE trial series, this randomized pilot is designed to address the challenge of preventing restenosis (re-narrowing of a blood vessel following treatment), a common occurrence in patients with peripheral artery disease (PAD).

U.S. Imaging Equipment Servicing Market Millenium Market Research Group

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the U.S. market for diagnostic imaging equipment servicing will grow slowly to a value of just over $2.78 billion by 2017. Increases in diagnostic imaging system sales and the installed base will be counterbal
CorPath200 Detroit Medical Center Cardiovascular Institute

The Detroit Medical Center (DMC) announced that a team of heart specialists at its Cardiovascular Institute (CVI) has successfully conducted the Midwest's first-ever "robotic-assisted" coronary revascularization to relieve heart artery blockages.  The successful implementation of the pioneering new treatment procedure — unique in Michigan and so far performed at only three institutions in the United States — means that DMC heart care patients now have access to the world's most advanced treatment method for relieving  blockages in heart arteries, said CVI President Theodore L. Schreiber, M.D.

January 11, 2013 — Guided Interventions LLC, a startup company developing new, easier to use fractional flow reserve (FFR) a product to help cardiologists better assess the physiological impact of coronary artery blockages, has received a $250,000 investment commitment from nonprofit venture development organization JumpStart Inc.

 

In a recent LinkedIn Medical Device Group posting, it was noted that DuVal & Associates, P.A. filed a Citizen Petition and Petition for Stay of Action with the FDA, on behalf of the Minnesota Medical Device Alliance (MMDA). See: http://medgroup.biz/FDA-petition

Angioslide announced the closing of $6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments to complete the round.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now